Barclays Maintains Overweight on Sotera Health, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott has maintained an Overweight rating on Sotera Health (NASDAQ:SHC) and increased the price target from $17 to $19.
February 28, 2024 | 4:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays has maintained an Overweight rating on Sotera Health and raised the price target from $17 to $19.
The upgrade in price target by a reputable analyst like Luke Sergott from Barclays signals a positive outlook on Sotera Health's stock. This is likely to instill confidence among investors, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100